Prelude Therapeutics Inc (PRLD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Prelude Therapeutics Inc (PRLD) has a cash flow conversion efficiency ratio of -0.327x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.11 Million) by net assets ($58.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PRLD company net worth for the company's overall valuation and market capitalisation.
Prelude Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Prelude Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Prelude Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prelude Therapeutics Inc ranked by their cash flow conversion efficiency. See PRLD operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eimco Elecon (India) Limited
NSE:EIMCOELECO
|
0.013x |
|
Leoch International Technology Limited
F:0LT
|
-0.006x |
|
Hooker Furniture Corporation
NASDAQ:HOFT
|
0.085x |
|
Acusensus Ltd
AU:ACE
|
0.023x |
|
Affinity Bancshares Inc
NASDAQ:AFBI
|
0.034x |
|
Endomines Finland Oyj
HE:PAMPALO
|
0.142x |
|
Tectonic Metals Inc
V:TECT
|
-0.483x |
|
LENZ Therapeutics Inc
NASDAQ:LENZ
|
-0.116x |
Annual Cash Flow Conversion Efficiency for Prelude Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Prelude Therapeutics Inc from 2018 to 2024. View Prelude Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $131.46 Million | $-102.89 Million | -0.783x | -73.32% |
| 2023-12-31 | $237.09 Million | $-107.06 Million | -0.452x | -5.40% |
| 2022-12-31 | $195.44 Million | $-83.73 Million | -0.428x | -46.63% |
| 2021-12-31 | $285.90 Million | $-83.53 Million | -0.292x | -34.25% |
| 2020-12-31 | $212.18 Million | $-46.18 Million | -0.218x | -141.90% |
| 2019-12-31 | $-49.41 Million | $-25.66 Million | 0.519x | -9.01% |
| 2018-12-31 | $-22.69 Million | $-12.95 Million | 0.571x | -- |
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and oral… Read more